159 related articles for article (PubMed ID: 20717995)
1. Epigenetic silencing of SOCS3 identifies a subset of prostate cancer with an aggressive behavior.
Pierconti F; Martini M; Pinto F; Cenci T; Capodimonti S; Calarco A; Bassi PF; Larocca LM
Prostate; 2011 Feb; 71(3):318-25. PubMed ID: 20717995
[TBL] [Abstract][Full Text] [Related]
2. SOCS3 Immunohistochemical Expression Seems to Support the 2005 and 2014 International Society of Urological Pathology (ISUP) Modified Gleason Grading System.
Pierconti F; Martini M; Cenci T; Petrone GL; Ricci R; Sacco E; Bassi PF; Larocca LM
Prostate; 2017 May; 77(6):597-603. PubMed ID: 28144985
[TBL] [Abstract][Full Text] [Related]
3. Prognostic relevance of SOCS3 hypermethylation in patients with glioblastoma multiforme.
Martini M; Pallini R; Luongo G; Cenci T; Lucantoni C; Larocca LM
Int J Cancer; 2008 Dec; 123(12):2955-60. PubMed ID: 18770864
[TBL] [Abstract][Full Text] [Related]
4. Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications.
Guan M; Zhou X; Soulitzis N; Spandidos DA; Popescu NC
Clin Cancer Res; 2006 Mar; 12(5):1412-9. PubMed ID: 16533763
[TBL] [Abstract][Full Text] [Related]
5. Frequent 14-3-3 sigma promoter methylation in benign and malignant prostate lesions.
Henrique R; Jerónimo C; Hoque MO; Carvalho AL; Oliveira J; Teixeira MR; Lopes C; Sidransky D
DNA Cell Biol; 2005 Apr; 24(4):264-9. PubMed ID: 15812243
[TBL] [Abstract][Full Text] [Related]
6. The Immunohistochemical Analysis of SOCS3 Protein Identifies a Subgroup of Prostatic Cancer Biopsies With Aggressive Behavior.
Pierconti F; Martini M; Cenci T; Larocca LM
Appl Immunohistochem Mol Morphol; 2018; 26(5):324-329. PubMed ID: 27801727
[TBL] [Abstract][Full Text] [Related]
7. Methylation-associated dysregulation of the suppressor of cytokine signaling-3 gene in multiple myeloma.
Wilop S; van Gemmeren TB; Lentjes MH; van Engeland M; Herman JG; Brümmendorf TH; Jost E; Galm O
Epigenetics; 2011 Aug; 6(8):1047-52. PubMed ID: 21934357
[TBL] [Abstract][Full Text] [Related]
8. GSTP1 hypermethylation as a molecular marker in the diagnosis of prostatic cancer: is there a correlation with clinical stage, Gleason grade, PSA value or age?
Bastian PJ; Ellinger J; Schmidt D; Wernert N; Wellmann A; Müller SC; von Rücker A
Eur J Med Res; 2004 Nov; 9(11):523-7. PubMed ID: 15649863
[TBL] [Abstract][Full Text] [Related]
9. CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer.
Enokida H; Shiina H; Igawa M; Ogishima T; Kawakami T; Bassett WW; Anast JW; Li LC; Urakami S; Terashima M; Verma M; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
Cancer Res; 2004 Sep; 64(17):5956-62. PubMed ID: 15342374
[TBL] [Abstract][Full Text] [Related]
10. Methylation status of the SOCS3 gene in human malignant melanomas.
Tokita T; Maesawa C; Kimura T; Kotani K; Takahashi K; Akasaka T; Masuda T
Int J Oncol; 2007 Mar; 30(3):689-94. PubMed ID: 17273770
[TBL] [Abstract][Full Text] [Related]
11. A quantitative promoter methylation profile of prostate cancer.
Jerónimo C; Henrique R; Hoque MO; Mambo E; Ribeiro FR; Varzim G; Oliveira J; Teixeira MR; Lopes C; Sidransky D
Clin Cancer Res; 2004 Dec; 10(24):8472-8. PubMed ID: 15623627
[TBL] [Abstract][Full Text] [Related]
12. DNA methylation paradigm shift: 15-lipoxygenase-1 upregulation in prostatic intraepithelial neoplasia and prostate cancer by atypical promoter hypermethylation.
Kelavkar UP; Harya NS; Hutzley J; Bacich DJ; Monzon FA; Chandran U; Dhir R; O'Keefe DS
Prostaglandins Other Lipid Mediat; 2007 Jan; 82(1-4):185-97. PubMed ID: 17164146
[TBL] [Abstract][Full Text] [Related]
13. Role of SOCS3 evaluated by immunohistochemical analysis in a cohort of patients affected by prostate cancer: preliminary results.
Calarco A; Pinto F; Pierconti F; Sacco E; Marrucci E; Totaro A; Palermo G; Vittori M; Bassi P
Urologia; 2012 Dec; 79 Suppl 19():4-8. PubMed ID: 22865333
[TBL] [Abstract][Full Text] [Related]
14. Adiponectin as a potential tumor suppressor inhibiting epithelial-to-mesenchymal transition but frequently silenced in prostate cancer by promoter methylation.
Tan W; Wang L; Ma Q; Qi M; Lu N; Zhang L; Han B
Prostate; 2015 Aug; 75(11):1197-205. PubMed ID: 25877612
[TBL] [Abstract][Full Text] [Related]
15. I105V polymorphism and promoter methylation of the GSTP1 gene in prostate adenocarcinoma.
Jerónimo C; Varzim G; Henrique R; Oliveira J; Bento MJ; Silva C; Lopes C; Sidransky D
Cancer Epidemiol Biomarkers Prev; 2002 May; 11(5):445-50. PubMed ID: 12010858
[TBL] [Abstract][Full Text] [Related]
16. Functional Loss of the gamma-catenin gene through epigenetic and genetic pathways in human prostate cancer.
Shiina H; Breault JE; Basset WW; Enokida H; Urakami S; Li LC; Okino ST; Deguchi M; Kaneuchi M; Terashima M; Yoneda T; Shigeno K; Carroll PR; Igawa M; Dahiya R
Cancer Res; 2005 Mar; 65(6):2130-8. PubMed ID: 15781623
[TBL] [Abstract][Full Text] [Related]
17. MT1G hypermethylation is associated with higher tumor stage in prostate cancer.
Henrique R; Jerónimo C; Hoque MO; Nomoto S; Carvalho AL; Costa VL; Oliveira J; Teixeira MR; Lopes C; Sidransky D
Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1274-8. PubMed ID: 15894685
[TBL] [Abstract][Full Text] [Related]
18. Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer.
Ogishima T; Shiina H; Breault JE; Tabatabai L; Bassett WW; Enokida H; Li LC; Kawakami T; Urakami S; Ribeiro-Filho LA; Terashima M; Fujime M; Igawa M; Dahiya R
Clin Cancer Res; 2005 Feb; 11(3):1028-36. PubMed ID: 15709168
[TBL] [Abstract][Full Text] [Related]
19. DLEC1, a 3p tumor suppressor, represses NF-κB signaling and is methylated in prostate cancer.
Zhang L; Zhang Q; Li L; Wang Z; Ying J; Fan Y; He Q; Lv T; Han W; Li J; Yang Y; Xu B; Wang L; Liu Q; Sun Y; Guo Y; Tao Q; Jin J
J Mol Med (Berl); 2015 Jun; 93(6):691-701. PubMed ID: 25648635
[TBL] [Abstract][Full Text] [Related]
20. Multigene methylation analysis for detection and staging of prostate cancer.
Enokida H; Shiina H; Urakami S; Igawa M; Ogishima T; Li LC; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
Clin Cancer Res; 2005 Sep; 11(18):6582-8. PubMed ID: 16166436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
